Bladder cancer is a global health issue with sex differences in incidence and prognosis.
Bladder cancer has distinct molecular subtypes with multiple pathogenic pathways …

Bladder cancer accounts for nearly 170,000 deaths worldwide annually. For over 4 decades,
the systemic management of muscle‐invasive and advanced bladder cancer has primarily …

This Seminar presents the current best practice for the diagnosis and management of
bladder cancer. The scope of this Seminar ranges from current challenges in pathology …

The number of cancer survivors continues to increase in the United States because of the
growth and aging of the population as well as advances in early detection and treatment. To …

Context Management of bladder cancer (BC) is primarily driven by stage, grade, and
biological potential. Knowledge of each is derived using clinical, histopathological, and …

The number of cancer survivors continues to increase in the United States due to the growth
and aging of the population as well as advances in early detection and treatment. To assist …

Purpose: This multidisciplinary, evidence-based guideline for clinically non-metastatic
muscle-invasive bladder cancer focuses on the evaluation, treatment and surveillance of …

Background Tri-modality therapy (TMT) is a recognized treatment strategy for selected
patients with muscle-invasive bladder cancer (MIBC). Objective Report long-term outcomes …

Purpose Multidisciplinary management improves complex treatment decision making in
cancer care, but its impact for bladder cancer (BC) has not been documented. Although …

Bladder cancer is a complex disease associated with high morbidity and mortality rates if not
treated optimally. Awareness of haematuria as the major presenting symptom is paramount …